The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PVCT | -36.5% | +6.12% | +1.19% | -93% |
| S&P | +18.54% | +92.9% | +14.04% | +519% |
Provectus Biopharmaceuticals, Inc. is a development stage biopharmaceutical company, which engages in the development of ethical pharmaceuticals for oncology and dermatology indications. Its prescription drugs treat several life-threatening cancers including metastatic melanoma, liver cancer, and breast cancer. The company was founded by Eric A. Wachter in 2002 and is headquartered in Knoxville, TN.
Do short-sellers have these three stocks pegged? You be the judge!
Down by double digits in just a few days. Why these 3 health-care stocks were the most horrendous performers this week.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.06M | -77.5% |
| Gross Profit | $0.06M | -77.4% |
| Gross Margin | 99.19% | 0.1% |
| Market Cap | $31.49M | -40.5% |
| Market Cap / Employee | $5.25M | 0.0% |
| Employees | 6 | 50.0% |
| Net Income | -$1.85M | -118.7% |
| EBITDA | -$1.68M | -155.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.42M | -29.3% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.10M | 0.0% |
| Short Term Debt | $2.41M | -20.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -802.65% | -583.2% |
| Return On Invested Capital | 66.52% | -16.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.52M | 31.4% |
| Operating Free Cash Flow | -$0.52M | 31.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -5.46 | -9.28 | -7.04 | -6.15 | -13.12% |
| Price to Sales | 56.79 | 81.79 | 63.90 | 68.43 | -11.53% |
| Price to Tangible Book Value | -5.46 | -9.28 | -7.04 | -6.15 | -13.08% |
| Enterprise Value to EBITDA | -57.46 | -23.43 | -45.25 | -20.06 | -76.22% |
| Total Debt | $2.80M | $3.18M | $2.58M | $2.51M | -17.50% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
